CN106749494B - 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 - Google Patents
具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN106749494B CN106749494B CN201710065183.9A CN201710065183A CN106749494B CN 106749494 B CN106749494 B CN 106749494B CN 201710065183 A CN201710065183 A CN 201710065183A CN 106749494 B CN106749494 B CN 106749494B
- Authority
- CN
- China
- Prior art keywords
- alkene
- olive
- acid
- pyrazine
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
Cell Line | Paclitaxel | 实施例1 | 实施例1 (5 μM) | 实施例1 (10 μM) |
KBV | 377.55 nM | >100 μM | 9.68 nM | 2.39 nM |
MCF-7/T | 78.52 nM | >100 μM | 15.04 nM | 4.57 nM |
MCF-7/ADR | 1623.92 nM | >100 μM | 388.45 nM | 331.31 nM |
Cell Line | 实施例1 (5 μM) | 实施例1 (10 μM) |
KBV | 39.0 | 158.0 |
MCF-7/T | 5.2 | 17.2 |
MCF-7/ADR | 4.18 | 4.90 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710065183.9A CN106749494B (zh) | 2017-02-06 | 2017-02-06 | 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710065183.9A CN106749494B (zh) | 2017-02-06 | 2017-02-06 | 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106749494A CN106749494A (zh) | 2017-05-31 |
CN106749494B true CN106749494B (zh) | 2019-03-12 |
Family
ID=58956592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710065183.9A Active CN106749494B (zh) | 2017-02-06 | 2017-02-06 | 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106749494B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112159455A (zh) * | 2020-10-28 | 2021-01-01 | 烟台大学 | 一种夫西地酸a环并氨基噻唑环衍生物及制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108794564B (zh) * | 2018-08-03 | 2021-01-19 | 烟台大学 | 常春藤皂苷元a环并吡嗪衍生物及其制备方法和用途 |
CN110964078B (zh) * | 2018-09-28 | 2021-03-23 | 薪火炙药(北京)科技有限公司 | 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用 |
CN112076200B (zh) * | 2020-10-28 | 2022-01-11 | 烟台大学 | 常春藤皂苷元聚乙二醇衍生物的应用 |
CN112175037B (zh) * | 2020-10-28 | 2021-07-02 | 烟台大学 | 常春藤皂苷元聚乙二醇衍生物及其制备方法 |
CN113527405B (zh) * | 2021-06-24 | 2022-12-20 | 烟台大学 | 常春藤皂苷元聚乙二醇修饰的衍生物制备肿瘤耐药逆转剂的应用 |
CN113234117A (zh) * | 2021-06-24 | 2021-08-10 | 烟台大学 | 常春藤皂苷元c-28位聚乙二醇修饰的衍生物及其制备方法 |
CN114213501B (zh) * | 2022-01-01 | 2023-01-20 | 烟台大学 | A环并异噁唑环常春藤皂苷元c-23位含氮杂环衍生物及其制备方法 |
CN114191439B (zh) * | 2022-01-01 | 2023-04-25 | 烟台大学 | A环并异噁唑环常春藤皂苷元c-23位含氮杂环衍生物的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485667A (zh) * | 2009-02-10 | 2009-07-22 | 浙江大学 | 雷公藤内酯醇的药物用途 |
CN102108092A (zh) * | 2011-01-29 | 2011-06-29 | 暨南大学 | 23-羟基白桦酸衍生物及其制备方法和用途 |
CN103570790A (zh) * | 2012-08-07 | 2014-02-12 | 中国科学院上海药物研究所 | 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途 |
CN105985399A (zh) * | 2015-02-04 | 2016-10-05 | 中国药科大学 | (20S,24R/S)-环氧-12β,25-羟基-达玛烷-3β-胺衍生物的制备方法和用途 |
-
2017
- 2017-02-06 CN CN201710065183.9A patent/CN106749494B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485667A (zh) * | 2009-02-10 | 2009-07-22 | 浙江大学 | 雷公藤内酯醇的药物用途 |
CN102108092A (zh) * | 2011-01-29 | 2011-06-29 | 暨南大学 | 23-羟基白桦酸衍生物及其制备方法和用途 |
CN103570790A (zh) * | 2012-08-07 | 2014-02-12 | 中国科学院上海药物研究所 | 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途 |
CN105985399A (zh) * | 2015-02-04 | 2016-10-05 | 中国药科大学 | (20S,24R/S)-环氧-12β,25-羟基-达玛烷-3β-胺衍生物的制备方法和用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112159455A (zh) * | 2020-10-28 | 2021-01-01 | 烟台大学 | 一种夫西地酸a环并氨基噻唑环衍生物及制备方法 |
CN112159455B (zh) * | 2020-10-28 | 2021-12-24 | 烟台大学 | 一种夫西地酸a环并氨基噻唑环衍生物及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106749494A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106749494B (zh) | 具有肿瘤耐药逆转活性的α-常春藤皂苷元衍生物及其制备方法和用途 | |
Ahmed et al. | Design, synthesis and antiproliferative activity of functionalized flavone-triazole-tetrahydropyran conjugates against human cancer cell lines | |
WO2017035982A1 (zh) | 一类邻萘醌化合物、其制备方法和医药用途 | |
Kumar et al. | Synthesis and biological evaluation of bergenin-1, 2, 3-triazole hybrids as novel class of anti-mitotic agents | |
MX2011004643A (es) | Compuestos acenafto heterocíclico, compuestos de inclusión y complejos con ciclodextrina y sus usos en la fabricación de inhibidores de proteínas de la familia bcl-2, análogos de bh3. | |
CA3029911C (en) | Antimetastatic 2h-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
Gao et al. | Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics | |
WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
CN107987081A (zh) | 一种新型二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用 | |
CN106220706B (zh) | 一种α-常春藤皂苷元衍生物及其制备方法和用途 | |
CN113150058A (zh) | 一种雷公藤红素衍生物及其制备方法和应用 | |
CN110156822B (zh) | 一种萘酚-苯硼酸类化合物及其制备方法和用途 | |
CN114195814A (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
Dei et al. | Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR) | |
CN104327156B (zh) | 二氢卟吩类光、声敏剂及其制备方法与应用 | |
Gordaliza et al. | Cytotoxic cyclolignans related to podophyllotoxin | |
Lu et al. | Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents | |
Raffa et al. | Anthranilamide-based 2-phenylcyclopropane-1-carboxamides, 1, 1'-biphenyl-4-carboxamides and 1, 1'-biphenyl-2-carboxamides: Synthesis biological evaluation and mechanism of action | |
Jia et al. | Synthetic dibenzoxanthene derivatives induce apoptosis through mitochondrial pathway in human hepatocellular cancer cells | |
Karabulut et al. | Synthesis of novel dimeric compounds containing triazole using click method and their selective antiproliferative and proapoptotic potential via mitochondrial apoptosis signaling | |
CN104854082A (zh) | 3,5,n-三羟基烷酰胺及其衍生物、及其制造方法与用途 | |
CN103804388B (zh) | 4β-氮取代呋喃叔胺类鬼臼毒素衍生物及其制备方法与应用 | |
JP6404220B2 (ja) | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 | |
CN104098457B (zh) | 四氢姜黄素类似物及其制备和应用 | |
Zhou et al. | Design, synthesis and anti-tumor activities of carbamate derivatives of cinobufagin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170531 Assignee: Shandong Luye Pharmaceutical Co.,Ltd. Assignor: Yantai University Contract record no.: X2020990000068 Denomination of invention: Alpha-hederagenin derivative with tumor drug-resisting reversion activity as well as preparation method and application thereof Granted publication date: 20190312 License type: Common License Record date: 20200210 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: With tumor drug resistance reversal activity a- Ivy saponin derivative and its preparation method and Application Effective date of registration: 20211214 Granted publication date: 20190312 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: Yantai University Registration number: Y2021980014850 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220317 Granted publication date: 20190312 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: Yantai University Registration number: Y2021980014850 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |